Theory Paper IIIDrNB Cardiology – Theory Notes

CORONARY FLOW RESERVE (CFR) ASSESSMENT

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IOVERVIEW

  • Definition: Coronary Flow Reserve (CFR) is the ratio of maximal hyperemic myocardial blood flow (during exercise or pharmacological vasodilation) to resting myocardial blood flow.
  • Integrated Scope: Represents the integrated vasodilatory capacity of the entire coronary arterial tree, encompassing both the epicardial conductance arteries and the microvascular resistance vessels (pre-arterioles, arterioles, and capillaries).
  • Clinical Role: In contemporary guidelines (ESC 2024 Chronic Coronary Syndromes Guidelines), CFR has transitioned from a research metric to a core clinical diagnostic parameter for phenotyping patients with Angina/Ischemia with Non-Obstructive Coronary Arteries (ANOCA / INOCA).

IICORONARY AUTOREGULATION AND PHYSIOLOGY

  • Resting Autoregulation: Under basal resting conditions, coronary arteriolar tone maintains high microvascular resistance so that resting coronary blood flow matches baseline myocardial oxygen demand (MVO2) across a wide range of perfusion pressures.
  • Hyperemic Reserve Capacity: During maximal endothelium-independent pharmacological vasodilation (induced by intravenous Adenosine at 140 mcg/kg/min or intracoronary papaverine/adenosine), microvascular resistance drops to a minimum; a normal healthy coronary bed increases blood flow 3- to 5-fold above baseline (CFR >= 2.0 to 2.5).
  • Flow vs. Pressure (CFR vs. FFR): Whereas Fractional Flow Reserve (FFR) is a pressure-derived ratio specific to the epicardial artery and largely independent of resting hemodynamics, CFR is a flow-derived ratio across the epicardial + microvascular bed and is directly influenced by resting heart rate, blood pressure, and ventricular contractility.

IIIMATHEMATICAL CALCULATION OF CFR BY MODALITY

  • Fundamental Theoretical Ratio:
    • Formula: CFR = Maximum Hyperemic Myocardial Blood Flow / Resting Myocardial Blood Flow.
    • Invasive Bolus Thermodilution (Pressure-Temperature Sensor Guidewire):
    • Formula: CFRthermo = Mean Transit Time at Rest (Tmn-rest) / Mean Transit Time at Hyperemia (Tmn-hyp).
    • Technical Principle: Because faster blood flow during hyperemia results in a shorter transit time for a 3-mL room-temperature saline bolus to travel down the coronary artery, resting transit time (the larger number) is placed in the numerator so that normal CFR exceeds 1.0 (and typically exceeds 2.0).
    • Invasive Doppler Flow Velocity (Doppler-Tipped Guidewire):
    • Formula: CFRDoppler = Average Peak Velocity at Hyperemia (APVhyp) / Average Peak Velocity at Rest (APVrest).
    • Technical Principle: Because volumetric flow is directly proportional to flow velocity, hyperemic velocity (the larger number) is placed in the numerator.
    • Non-Invasive Quantitative Positron Emission Tomography (Cardiac PET):
    • Formula: CFRPET (Myocardial Flow Reserve) = Hyperemic Myocardial Blood Flow (in mL/min/g) / Resting Myocardial Blood Flow (in mL/min/g).
Assessment Modality Invasive vs. Non-Invasive Calculation Formula Key Advantage & Simultaneous Metrics
Bolus Thermodilution Wire Invasive (Cath Lab) Tmn(Rest) / Tmn(Hyperemia) Simultaneous FFR, CFR, & IMR on a single pressure-temperature wire
Doppler Velocity Wire Invasive (Cath Lab) APV(Hyperemia) / APV(Rest) Direct velocity measurement + Hyperemic Microvascular Resistance (HMR)
Quantitative Cardiac PET Non-Invasive Gold Standard MBF(Hyperemia) / MBF(Rest) (mL/min/g) Absolute flow quantification across all three coronary territories
Transthoracic Doppler Echo / Stress CMR Non-Invasive Distal LAD peak diastolic velocity ratio / MPRI Radiation-free, lower cost (Echo limited by acoustic window)

IVCLINICAL APPLICATIONS OF CFR

  • Diagnosing Coronary Microvascular Dysfunction (CMD) in ANOCA / INOCA: In patients with anginal symptoms and unobstructed epicardial arteries (FFR > 0.80), a CFR less than 2.0 (combined with an Index of Microcirculatory Resistance [IMR] >= 25 or Hyperemic Microvascular Resistance [HMR] >= 2.5 mmHg/cm/s) confirms Coronary Microvascular Dysfunction and guides targeted therapy with beta-blockers, ACE inhibitors, statins, ranolazine, or nicorandil.
  • Discordant Epicardial Disease (FFR vs. CFR Discordance): Integrating FFR and CFR distinguishes focal epicardial stenosis with healthy microvasculature (Low FFR <=0.80 / Normal CFR >=2.0), which benefits from PCI, from diffuse epicardial disease or severe microvascular disease (Normal FFR >0.80 / Low CFR <2.0), where stenting is ineffective and medical therapy is indicated.
  • Heart Failure with Preserved Ejection Fraction (HFpEF): Impaired CFR (< 2.0) is present in up to 70 percent of patients with HFpEF, reflecting systemic endothelial inflammation and capillary rarefaction, and independently predicts HF hospitalization.

VLIMITATIONS AND TECHNICAL CHALLENGES

  • Sensitivity to Resting Hemodynamics: Because resting blood flow is the denominator of the CFR equation, any condition that elevates resting myocardial oxygen demand and resting flow—such as sinus tachycardia, systemic hypertension, Left Ventricular Hypertrophy (LVH), elevated LVEDP, or anemia—mathematically lowers the calculated CFR even when maximal hyperemic flow is preserved (Rate-Pressure Product-corrected resting flow is used to adjust for this).
  • Lack of Epicardial vs. Microvascular Specificity in Isolation: A low CFR alone cannot distinguish between a severe epicardial stenosis and primary microvascular disease unless paired with FFR (invasive) or regional perfusion defects (PET).
  • Technical Pitfalls in the Cath Lab:
    • Submaximal Hyperemia: Caffeine or methylxanthine intake within 12 to 24 hours competitively blocks adenosine A2A receptors, causing falsely low hyperemic flow and false-positive CFR results.
    • Thermodilution Bolus Variability: Requires the average of at least 3 consistent rapid 3-mL room-temperature saline injections with the guide catheter coaxial and disengaged from wedging.
    • Doppler Signal Quality: Requires careful wire-tip rotation to maintain a crisp spectral velocity envelope in the center of the vessel lumen.

VILANDMARK EVIDENCE, GUIDELINES AND THE INDIAN CONTEXT

  • CorMicA Trial (JACC 2018) and ESC 2024 CCS Guidelines (Class I): The CorMicA Trial proved that stratified medical therapy guided by invasive CFR, IMR, and acetylcholine testing significantly improves angina and quality of life in ANOCA patients, earning an upgraded Class I (Level B) recommendation for invasive coronary functional testing in persistently symptomatic ANOCA patients in the 2024 ESC Chronic Coronary Syndromes Guidelines.
  • Application in the Indian Context: Given the high prevalence of Diabetes Mellitus and microvascular disease in Indian patients presenting with angina and non-obstructive epicardial arteries, Transthoracic Doppler Echocardiographic CFR of the distal LAD serves as a practical, low-cost non-invasive screening tool in resource-limited settings prior to invasive wire-based testing.

Key references

  • Vrints C, Andreotti F, Koskinas KC, et al.: 2024 ESC Guidelines for the management of chronic coronary syndromes, European Heart Journal, 2024.
  • Ford TJ, Stanley B, Good R, et al. (CorMicA Investigators): Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial, Journal of the American College of Cardiology, 2018.
  • Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Ed., Elsevier, 2022.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.